This article reviews the vertical integration of pharmaceutical manufacturers between 1993 and 1995. The objective of these strategies was to take control of Pharmacy Benefits Managers (PBMs), to enable drug-manufacturing firms to strengthen their market power by securing an outlet for their drugs. The difficulties that appeared during these operations, and how laboratories were pressed (with the exception of Merck laboratories) to put an end to these acquisitions are analyzed. Risks of competition distortion that these strategies may lead to is also discussed. Drug manufacturing firms were not able to gain the strategic advantages, (e.g. market control), they expected because of legal limitations imposed by authorities, high penal risk and physician hostility.
AcsZ.AudretschD. (1990) Innovation and small firms (Cambridge, MA: MIT Press).
2.
AdvanceTech Monitor (1999) Pharmacogemics: Impact on drug discovery.
3.
AlchianA.A.DemsetzH. (1972) Production, information costs and economic organization, American Economic Review, 62: 777–795.
4.
American College of Physicians – American Society of Internal Medicine (2001) Ambulatory care formularies and pharmacy benefit management by managed care organizations, White Paper.
5.
AokiM. (2002) Modularity: Its relevance to Industrial Architecture Conference 7–8 November (Paris: Le centre de recherche économique de Saint Gobain).
6.
ArrowK.J. (1975) Vertical integration and communication, Bell Journal of Economics, 6: 173–183.
7.
ArruñadaB.González-DíazM.FernándezA. (2004) Determinants of organizational form: Transaction costs and institutions in the European trucking industry, Industrial and Corporate Change, 13(6): 867–882.
8.
LittleArthur D. (2001) New Business Models for Breakthrough Growth (New York: Arthur D. Little).
9.
BaltoD.A. (1997) A whole new world? Pharmaceutical responses to the managed care revolution, Food and Drug Law Journal, 52: 83–98.
10.
BaumolW.PanzarJ.WilligR. (1982) Contestable Markets and the Theory of Industry Structure (San Diego, CA: Harcourt Brace Jovanovich).
11.
BaumolW.J. (1997) Musings on vertical integration, International Journal of Social Economics, 24(1/2/3): 16–27.
12.
BermanH. (1995) Tufts Associated Health Plan (Boston), cited in HMO-driven markets could hurt R&D, Script 2026, 19 May, p. 18.
13.
ChengS.S. (1999) Worldwide sales of prescription pharmaceuticals to 2002 (Waltham, M.A. Decision Resources).
14.
CoaseR.H. (1937) The nature of the firm, Economica, 4: 386–405.
15.
CockburnI.M.HendersonR.M.SternS. (2000) Untangling the origins of competitive advantage, Strategic Management Journal, 21: 1123–1145.
16.
D'AveniR.A.IlinitchA.Y. (1992) Complex patterns of vertical integration in the forest products industry: Systematic and bankruptcy risks, Academy of Management Journal, 35: 596–625.
17.
Department of Health and Human Services (DHHS) (1997) Experiences of HMOs with PBM Companies (Washington, DC: Office of the Inspector General (OIG)).
18.
DiChiaraR.PesanelloP. (1997) Tug-of-war over rebates, American Druggist, May.
19.
Federal Trade Commission (1998) Merck settles FTC charges that its acquisition of Medco could cause higher prices and reduced quality for prescription drugs, press release, 27 August.
FoxP.D.LatanichT.S.O'FlinnC.BrownP. (1999) The ABCs of PBMs, Issue Brief 749, National Health Policy Forum, 27 October, Washington, DC.
22.
FreudenheimM. (1996) Not quite what the doctor ordered: Drug substitutions add to discord over managed care, New York Times Section D: 1, 8 October.
23.
GalbraithG.K. (1952) American Capitalism: The Counterveiling Power (Boston: Houghton Mifflin).
24.
General Accounting Office (GAO) (1995) Pharmacy benefit managers: Early results of ventures with drug manufacturers, HEHS-96-45, 9 November, Washington, DC.
25.
GhemawatP.PorterM.RawlinsonR. (1986) Patterns of international coalition activity, in PorterM. (eds) Competition in Global Industries (Boston, MA: Harvard University Press), 345–365.
26.
GravesS.B.LangowitzN.S. (1993) Innovative productivity and returns to scale in the pharmaceutical industry, Strategic Management Journal, 14: 593–605.
27.
GreenM. (1996) Compromising Your Drug of choice: How HMOs are Dictating Your Next Prescription (New York: Public Advocate for the City of New York).
28.
GreenM. (1997) Pharmaceutical Payola: How Secret Commercial Deals are Dictating Your Next Prescription and Harming Your Health (New York: Public Advocate for the City of New York).
29.
GrunertK.G., (2005) A market orientation of value chains: A conceptual framework based on four case studies from the food industry, European Journal of Marketing, 39(5–6): 428–455.
30.
HagelJ.SingerM. (1999) Unbundling the corporation. Harvard Business Review, 77(2): 133–142.
31.
HamdouchA.DepretM.H. (2001) La nouvelle économie industrielle de la pharmacie (Paris: Elsevier).
32.
HarriganK.R. (1983) Strategies for Vertical Integration (Lexington, KY: D.C. Heath).
33.
HarriganK.R. (1984) Formulating vertical integration strategies, Academy of Management Review, 9(4): 638–652.
34.
HarrisonJ. (1994) Going upstream in drug marketing, Mergers & Acquisitions, 29(2): 43.
35.
HilzenrathD.S. (1997) Drug firms said to pressure doctors, Washington Post, 14 August.
36.
HornS.D.SharkeyP.D.TracyD.M.HornC.E.JamesB.GoodwinF. (1996) Intended and unintended consequences of HMO cost-containment strategies: Results from the managed care outcomes project, American Journal of Managed Care, II(3): 253–264.
37.
HughesS.J.KaoL.J. (2001) Vertical integration and proprietary information transmission, Journal of Economics and Management Strategy, 10: 277–299.
38.
JamesA.D. (2002) The strategic management of mergers and acquisitions in the pharmaceutical industry: Developing a resource-based perspective, Technology Analysis & Strategic Management, 14(3): 299–314.
39.
JohnstonR.LawrenceP.R. (1988) Beyond vertical integration: The rise of the value-adding partnership, Harvard Business Review, 66(4): 94–101.
40.
KellyF. (1998) Lyme disease alleged to be false diagnosis, Ann Arbor News, 9 June.
41.
KrelingD.H.LiptonH.L.CollinsT.HerzK.C. (1996) Assessment of the impact of Pharmacy Benefit Managers: Final Report to the Health Care Financing Administration, publication number PB97-103683, National Technical Information Service, Springfield, Virginia.
42.
LevyR. (1999) The Pharmaceutical Industry: A Discussion of Anticompetitive and Antitrust Issues in an Environment of Change (Washington, DC: Federal Trade Commission).
43.
McCarthyR. (1999) How well does your PBM perform?, Business & Health, 17(1):.
44.
McGahanA. (1994) Focus on pharmaceuticals: Industry structure and competitive advantage, Harvard Business Review, November–December, 115–24.
45.
MånssonJ. (2004) Vertical integration and efficiency: Ownership in the Swedish sawmill industry, Review of Industrial Organization, 24(1): 25–36.
46.
MartinezB. (2002) Medco finds that old ties bind in contract with parent Merck after spinoff, Wall Street Journal, 15 May.
47.
MilliouC. (2004) Vertical integration and R&D information flow: Is there a need for ‘firewalls’?, International Journal of Industrial Organization, 22: 25–43.
48.
MitchellE.L. (1999) The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: The need for a new regulatory approach, Food And Drug Law Journal, 54(1): 151–183.
PeatS. (1999) HMO and PBM Strategies for Pharmacy Benefits (Washington DC: Atlantic Information Services (AIS)).
55.
Peri Iz/PricewaterhouseCoopers LLP (2001) HCFA study of the pharmaceutical benefit management industry (New York: PriceWaterhouseCoopers).
56.
PerryM.K. (1989) Vertical integration: Determinants and effects, in SchmalenseeR.WilligR. D. (eds) Handbook of Industrial Organization, VolumeI (Amsterdam: Elsevier), 183183–255255.
57.
Pharmacy Benefit Management Institute Inc. (1998) HMO-PBM Market Share and Formulary Management (Scottsdale, AE).
58.
PioreM.J.SableC.F. (1984) The Second Industrial Divide: Possibilities for Prosperity (New York: Basic Books).
59.
PorterM.E. (1980) Competitive Strategy: Techniques for Analyzing Industries and Competitors (New York: Free Press).
60.
PorterM.E. (1985) Competitive Advantage (New York: The Free Press).
61.
PorterM.E. (1990) The Competitive Advantage of Nations (New York: Free Press).
62.
PriceWaterhouseCoopers (1999) High-performing strategic alliances in the pharmaceutical, biotechnology and medical device and diagnostic industries (New York: PriceWaterhouse Coopers.
63.
ReardonT.R. (1997) Pharmaceutical benefits management companies, Report of the board of trustees to the American Medical Association (AMA) House of Delegates (9-I-97).
RobbN. (1995) Some suffer adjustment pains as Blue Cross changes drug-benefit program on East Coast, Canadian Medical Association Journal, 153(3): 339–341.
66.
RosenthalE. (1997) Maker of cancer drugs to oversee prescriptions at 11 cancer centers, New York Times, 15 April.
67.
SchulmanK.A.RubensteinE.AbernethyD.R.SeilsD.M.SulmasyD.P. (1996) The effect of pharmaceutical benefits managers: Is it being evaluated?, Annals of Internal Medicine, 124: 906–913.
68.
ShulmanS.R.LasagnaL. (1998) PBMs of the 1990s: Why they deserve a second look, in ShulmanS. R.HealyE. M.LasagnaL. (eds) PBMs: Reshaping the Pharmaceutical Distribution Network (Binghamton, NY: Pharmaceutical Products Press).
69.
SmithJ.G.FleckV. (1988) Strategies of new biotechnology firms, Long Range Planning, 21(3): 51–58.
70.
SteinC.M.WoodA.J.PincusT. (1997) Implementation of multiple outpatient formularies: Undesirable effects, Clinical Pharmacology and Therapeutics, 61: 1–7.
71.
TaniguchiR. (1995) Pharmacy benefit management companies, American Journal of Health-System Pharmacists, 52: 1915–1917.
72.
TanouyeE. (1996) Owning a pharmacy benefit manager may not make much difference, Wall Street Journal, 11 November.
73.
WillcoxS.HimmelsteinD.WoolhandlerS. (1994) Inappropriate drug prescribing for the community – dwelling elderly, JAMA272(4): 292–6.
74.
WilliamsonO.E. (1975) Markets and Hierarchies: Analysis and Antitrust Implications (New York: Free Press).
75.
WoodwardD. (1996) The new drug marketing: A consumer protection perspective, Food and Drug Law Journal, 51: 637–650.
